All In Biotech

Drug Trial Radar · NCT07592273

Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

An Operationally Seamless Phase 2b/3, Multicenter, Randomized, Masked, Sham-controlled Study to Evaluate the Efficacy and Safety of Surabgene Lomparvovec (Sura-vec) Delivered Via Suprachoroidal Space (SCS) Injection Targeting Subjects With Diabetic Retinopathy Without Center Involved-Diabetic Macular Edema (CI-DME) (NAAVIGATE)

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 576 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

576

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Jun 2028

Study completion Jan 2036

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
May 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of the eye (called the retina). Over time, this damage can lead to vision problems and even blindness if not treated. This study will assess surabgene lomparvovec (sura-vec) as a potential one-time gene therapy administered in the suprachoroidal space (SCS) for the treatment of diabetic retinopathy (DR) and prevention of vision-threatening events (VTEs) in participants with non-proliferative DR (NPDR) without center-involved diabetic macular edema (CI-DME). This study will consist of 3 portions: a Phase 2b portion, a Phase 3 portion, and a bilateral treatment portion. Approximately 576 adult participants will be enrolled in the study across multiple sites in the United States and Puerto Rico. In the Phase 2b and Phase 3 portions, participants will be randomized to different groups to receive sura-vec and prophylactic steroids or sham and artificial tears in their study eye. If assigned to sham, participants will be given an opportunity to cross over and receive treatment with sura-vec. In the bilateral treatment portion, participants will be enrolled to receive sura-vec and prophylactic steroids in both eyes. In all 3 portions, follow-up in the study will continue through 5 years following administration of sura-vec in each eye. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Diabetic Retinopathy

Interventions

  • Surabgene LomparvovecDrug

    Solution Injection

  • ShamDrug

    needleless injection without fluid

  • Topical SteroidDrug

    Topical Drops

  • Artificial TearsDrug

    Topical Drops

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2B: Percentage of Participants Achieving >= 2-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study EyeTime frame: At Week 52
  2. Phase 3: Percentage of Participants Achieving >= 2-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study EyeTime frame: At Week 52
  3. Bilateral Portion: Bilateral portion: Number of participants experiencing ocular Adverse Events (AEs), Serious Adverse Events (SAEs), or any Adverse Events of Special Interest (AESIs)Time frame: Up to Approximately Week 104
  4. Bilateral Portion: Participants Who Experience Intraocular InflammationTime frame: Up to Approximately Week 104
  5. Bilateral Portion: Participants Who Experience Scleral Inflammation Including EpiscleritisTime frame: Up to Approximately Week 104

Locations

40 sites in 2 countries. Site status is shown where the registry gives one.

  • Barnet Dulaney Perkins Eye Center - Mesa /ID# 283000

    Mesa, Arizona · Recruiting

  • Retinal Consultants Of Arizona - Phoenix - North /ID# 283407

    Phoenix, Arizona · Recruiting

  • Retina Macula Institute of Arizona /ID# 282881

    Scottsdale, Arizona · Recruiting

  • California Retina Consultants - Bakersfield /ID# 282990

    Bakersfield, California · Recruiting

  • Retina-Vitreous Associates Medical Group - Beverly Hills /ID# 282995

    Beverly Hills, California · Recruiting

  • Retinal Diagnostic Center /ID# 275055

    Campbell, California · Recruiting

  • The Retina Partners /ID# 274741

    Encino, California · Recruiting

  • Northern California Retina Vitreous Associates /ID# 282994

    Mountain View, California · Recruiting

  • California Eye Specialists Medical Group /ID# 274705

    Pasadena, California · Recruiting

  • Retina Consultants San Diego /ID# 274748

    Poway, California · Recruiting

  • Retinal Consultants - Sacramento - Greenback Lane /ID# 283018

    Sacramento, California · Recruiting

  • West Coast Retinal Medical Group /ID# 283007

    San Francisco, California · Recruiting

  • California Retina Consultants - Santa Barbara /ID# 283050

    Santa Barbara, California · Recruiting

  • Macula Retina Vitreous Center - Torrance /ID# 282878

    Torrance, California · Recruiting

  • Bay Area Retina Associates /ID# 275032

    Walnut Creek, California · Recruiting

  • Southwest Retina Research Center /ID# 276094

    Durango, Colorado · Recruiting

  • Colorado Retina Associates /ID# 283006

    Lakewood, Colorado · Recruiting

  • Advanced Vision Surgery Center /ID# 275017

    Longmont, Colorado · Recruiting

  • Florida Retina Consultants - Lakeland /ID# 275012

    Lakeland, Florida · Recruiting

  • Florida Retina Institute - Orlando /ID# 283034

    Orlando, Florida · Recruiting

  • Retina Speciality Institute /ID# 274996

    Pensacola, Florida · Recruiting

  • Southeast Retina Center /ID# 274739

    Augusta, Georgia · Recruiting

  • Illinois Retina Associates S.C /ID# 283048

    Chicago, Illinois · Recruiting

  • University Retina - Lemont /ID# 283021

    Lemont, Illinois · Recruiting

  • Springfield Clinic - First /ID# 283028

    Springfield, Illinois · Recruiting

  • Retina Associates - Lenexa /ID# 283004

    Lenexa, Kansas · Recruiting

  • Maine Eye Center - Marginal Way Campus /ID# 275039

    Portland, Maine · Recruiting

  • Mid Atlantic Retina Specialists - Hagerstown /ID# 274725

    Hagerstown, Maryland · Recruiting

  • Sierra Eye Associates /ID# 274737

    Reno, Nevada · Recruiting

  • Retina Center Of New Jersey /ID# 283088

    Bloomfield, New Jersey · Recruiting

  • Retina Associates Of Cleveland - Middleburg Heights Office /ID# 275985

    Middleburg Heights, Ohio · Recruiting

  • Retina Northwest /ID# 283232

    Portland, Oregon · Recruiting

  • Charleston Neuroscience Institute - Charleston /ID# 275047

    Charleston, South Carolina · Recruiting

  • Austin Research Center for Retina /ID# 276101

    Austin, Texas · Recruiting

  • Retina and Vitreous of Texas /ID# 283051

    Bellaire, Texas · Recruiting

  • Star Retina /ID# 276513

    Burleson, Texas · Recruiting

  • Texas Retina Associates - Dallas /ID# 276117

    Dallas, Texas · Recruiting

  • Wagner Macula & Retina Center - Norfolk /ID# 275021

    Norfolk, Virginia · Recruiting

  • Vistar Eye Center - Salem /ID# 282879

    Salem, Virginia · Recruiting

  • Emanuelli Research & Development Center /ID# 275378

    Arecibo, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.